Key Highlights

  • Echo IQ (ASX:EIQ) traded at A$1.67 on 14 August 2026 at 1:01 pm, up A$0.077, or 4.83%, during the session.
  • The company reported more than 70 hospitals in its US commercial pipeline, including three enterprise proposals covering more than 300 hospitals.
  • EchoSolv AS processed more than 10,200 echocardiograms during the June quarter, a 20% quarter-on-quarter increase.
  • Echo IQ completed an approximately A$110 million institutional Placement and announced strategic relationships involving Pro Medicus, Advara HeartCare and Mayo Clinic.

Echo IQ (ASX:EIQ) was trading at A$1.67 on 14 August 2026 at 1:01 pm, representing an increase of A$0.077, or 4.83%, on the session. The latest market performance comes as the medical technology company progresses its US commercial expansion and develops its artificial intelligence platform for cardiovascular applications. The company's June-quarter activities also included new strategic relationships, additional Capital and increased activity across its commercial pipeline.

Share Price Performance and Commercial Expansion

Echo IQ's recent share price performance coincides with a period of expanding commercial activity for the company. During the June 2026 quarter, its US pipeline increased to more than 70 hospitals, while three enterprise proposals were reported to cover more than 300 hospitals.

The company also introduced EchoSolv VIEW and SHADOW enterprise deployment programs during the period. These programs provide additional pathways for introducing the EchoSolv platform into healthcare organisations as Echo IQ continues its US market expansion.

The commercial development is taking place alongside the company's existing focus on artificial intelligence applications in cardiology. Echo IQ uses AI-based technology and proprietary software intended to support clinical decision-making in cardiovascular care.

EchoSolv Processing Activity

EchoSolv AS processed more than 10,200 echocardiograms during the quarter ended 30 June 2026. This represented a 20% increase from the previous quarter and more than 400% growth compared with the corresponding period a year earlier.

The processing figures provide a measure of platform activity as Echo IQ continues to build its commercial presence. The company is also progressing regulatory work for EchoSolv HF, with its US FDA submission remaining under review during the period.

Echo IQ has indicated that preparations for a potential commercial launch of EchoSolv HF are continuing, subject to regulatory clearance.

Institutional Funding and Strategic Partnerships

Capital management was another significant feature of the period. Echo IQ completed an institutional placement of approximately A$110 million, with the funds designated for US commercial expansion, product development and the broader cardiovascular AI platform. The placement involved 75,862,069 new shares issued at A$1.45 each, according to the company's 1 July ASX announcement.

The company also entered into a binding Heads of Agreement with Pro Medicus Limited for a proposed strategic Investment of up to A$20 million and a US commercial partnership. The arrangement is intended to provide potential access to Pro Medicus' medical imaging platform and its US customer network.

Following the quarter, Echo IQ announced an exclusive data licensing agreement with Advara HeartCare. The arrangement provides access to as many as one million deidentified echocardiography studies and related clinical datasets for AI product development.

Research and Platform Development

Echo IQ's product-development activities also expanded through a research collaboration with Mayo Clinic. The collaboration is focused on evaluating the company's AI platform in cardiooncology, with the work intended to examine potential applications beyond its existing cardiovascular use cases.

The company has also expanded its executive leadership, clinical advisory network and US commercial team. These changes accompany the broader expansion of customer Acquisition and deployment activities in the United States.

The combination of commercial deployment, additional datasets and research collaborations forms the backdrop to Echo IQ's continuing development of its cardiovascular AI platform. Regulatory progress, customer conversion and the pace of platform utilisation remain central elements of the company's operating trajectory.

Conclusion

Echo IQ (ASX:EIQ) is entering the second half of 2026 with several parallel areas of activity, including US commercial expansion, regulatory progress, AI product development and strategic partnerships. The company reported more than 10,200 echocardiograms processed during the June quarter and a US pipeline exceeding 70 hospitals, while the A$110 million institutional placement provides funding for the stated expansion and development programs. The latest share price performance reflects the current market trading position, while subsequent company updates will provide further information on commercial deployments, regulatory outcomes and the development of its broader cardiovascular AI platform.